DDR2 gene deletion in a breast cancer mouse models has been shown to increase anti-PD-1 therapy sensitivity, and the combination of anti-PD-1 and DDR2 tyrosinase inhibitor Dasatinib reduces tumor burden (Tu et al., 2019). This evidence concerns the gene DDR2 and neoplasm.